



# National Institute of Standards & Technology

## Certificate of Analysis

### Standard Reference Material® 1951a

#### Lipids in Frozen Human Serum

Lot Nos. 95-LI and 95-LII

This Standard Reference Material (SRM) is intended primarily for use in evaluating the accuracy of clinical procedures for the determination of total cholesterol, HDL-cholesterol and LDL-cholesterol, and triglycerides (both total glyceride species and triglycerides only) in human serum. It is also intended for use in validating working or secondary reference materials. A unit of SRM 1951a consists of four bottles of frozen human serum, two bottles at each of two different analyte concentration levels. Each bottle contains 1 mL of human serum.

**Certified Concentration Values:** The certified concentrations of total cholesterol and triglycerides were determined at NIST by definitive methods [1]. The concentrations and their expanded uncertainties for the two concentration levels (SRM 1951a Level I and SRM 1951a Level II) are listed in Table 1a in mmol/L and in Table 1b in mg/dL (as triolein for the triglycerides). The triglycerides concentrations are reported two ways: as total glycerides (the molar sum of free glycerol, monoglycerides, diglycerides, and triglycerides); and as triglycerides only. The associated combined uncertainties and degrees of freedom are shown in Table 2. The certified concentrations apply only to serum thawed to room temperature, 20 °C to 25 °C (see Instructions for Use).

**Reference Concentration Values:** Reference concentration values for total cholesterol, HDL-cholesterol and LDL-cholesterol, triglycerides and glycerol blank, provided by the Lipid Reference Laboratory at the Centers for Disease Control and Prevention (CDC), are reported in Table 3. These results were determined using the CDC reference methods. The sum of these results for triglycerides and glycerol agree well with the NIST total glyceride concentrations in Table 1b. *The concentrations for HDL- and LDL-cholesterol have been revised based upon new data received from CDC. The other analytes were unchanged.*

**Expiration of Certification:** The certification of this SRM is valid from **30 September 1998 - Date Extend to 30 September 2000**, within the measurement uncertainties specified, provided the SRM is handled and stored in accordance with the instructions given in the certificate. However, the certification is nullified if the SRM is damaged, contaminated or modified.

The analytical measurements at NIST were performed by L.T. Sniegowski of the NIST Analytical Chemistry Division and P. Ellerbe, College of American Pathologists (CAP) Research Associate at NIST. The analytical measurements at CDC were performed by C. Griffin, S. Ethridge, and R. Cheek.

The sampling protocol and statistical analysis of the NIST data were performed by S.B. Schiller and M.G. Vangel of the NIST Statistical Engineering Division. Statistical analysis of the CDC data was provided by S.J. Smith of CDC.

The support aspects involved in the preparation, certification, and issuance of this SRM were coordinated through the Standard Reference Materials Program by J.C. Colbert.

Willie E. May, Chief  
Analytical Chemistry Division

Gaithersburg, MD 20899  
Revised Certificate Issue Date: 4 March 1999  
*See Certificate Revision History on Last Page*

Thomas E. Gills, Chief  
Standard Reference Materials Program

The overall direction and coordination of the analyses at NIST were under the chairmanship of M.J. Welch of the NIST Analytical Chemistry Division. The overall coordination of the analyses at CDC were under the direction of P.P. Waymack of the CDC Lipid Reference Laboratory.

## NOTICE AND WARNINGS TO USERS

SRM 1951a IS INTENDED FOR IN-VITRO DIAGNOSTIC USE ONLY. THIS IS A HUMAN SOURCE MATERIAL. HANDLE PRODUCT AS A BIOHAZARDOUS MATERIAL CAPABLE OF TRANSMITTING INFECTIOUS DISEASE. The supplier of this serum has reported that each donor unit of serum or plasma used in the preparation of this product was tested by an FDA approved method and was found to be nonreactive for HbsAG, HCV and HIV-1 antibodies. However, no known test method can offer complete assurance that hepatitis B virus, hepatitis C virus, HIV, or other infectious agents are absent from this material. Accordingly, this human blood-based product should be handled at the Biosafety Level 2 or higher as recommended for any POTENTIALLY INFECTIOUS HUMAN SERUM OR BLOOD SPECIMEN in the Centers for Disease Control/National Institutes of Health (NIH) Manual [2].

**Storage:** The serum is shipped frozen (on dry ice) and, upon receipt, should be stored frozen until ready for use. A freezer temperature of -20 °C is acceptable for storage up to one week. If a longer storage time is anticipated, the material should be stored at or below -50 °C. The SRM should not be exposed to sunlight or ultraviolet radiation. Storage of thawed material at room or refrigerator temperatures may result in changes in the analyte concentrations.

**Stability:** The material is kept at -80 °C for long term storage at NIST. Under these conditions, the total cholesterol and triglycerides are expected to be stable. NIST will continue to monitor the stability of these analytes in this material and will notify purchasers of the material of any changes in the certified concentrations.

**Instructions for Use:** Bottles of the SRM to be analyzed should be removed from the freezer and allowed to stand at room temperature until thawed. After the material is thawed to room temperature, it should be used immediately. The material should be swirled gently to mix it before aliquots are withdrawn.

## SOURCE, PREPARATION, AND ANALYSIS

**Source of Material:** SRM 1951a Lipids in Frozen Human Serum was prepared by the Solomon Park Research Laboratories, Kirkland, WA following a protocol developed by the Cholesterol Reference Materials Subcommittee of the National Committee for Clinical Laboratory Standards (NCCLS), under the chairmanship of G.L. Myers of the CDC. The goal of the NCCLS project was to develop a commutable lipid reference material for total cholesterol that would be useful in most presently available field methods. A large scale study of this material involving most of the major clinical measurement systems found no significant biases between results on this material and those from fresh, unpooled serum. This study verified that this material is an appropriate mechanism for transferring accuracy from the definitive and reference methods to the clinical laboratories. Further details of this study will be published elsewhere.

**Preparation of Material:** Donor units were collected and allowed to clot at room temperature for 4 h. The serum was removed from the clot and immediately cooled to approximately 4 °C. Each donor unit's serum was then analyzed for total cholesterol content to determine which donor units to pool. The donor units selected were then pooled. One milliliter aliquots of the bulk pool were dispensed into 3 mL glass bottles and frozen at -70 °C. This was accomplished within 50 h of the initial donor unit collection.

**Analytical Methods:** For the determination of the certified concentrations of the analytes (Tables 1a and 1b), a stratified sampling plan was devised to test for homogeneity across the manufacturing process. One group of samples was used for the determination of total cholesterol, a second set was used for the total glycerides and triglycerides. A method considered to be "definitive" [1] for total serum cholesterol by the NCCLS was used for the determination of total cholesterol [3]. A candidate definitive method was used for the determinations of total glycerides and triglycerides only [4]. Both methods use isotope dilution/gas chromatography/mass spectrometry. The material was found to be homogeneous for all analytes.

For the reference concentrations determined by the CDC (Table 2a), total cholesterol was determined using the National Reference Method for total cholesterol [5,6]. Determination of HDL-cholesterol was performed with the CDC HDL reference procedure using ultracentrifugation to remove triglyceride (VLDL) that may interfere with the heparin-Mn<sup>2+</sup> precipitation procedure [7]. LDL-cholesterol was measured indirectly using the beta-quantification procedure [7]. Triglyceride was determined using the modified CDC reference method which corrects for free glycerol, phospholipids, and other potential interfering substances through extraction with methylene chloride and treatment with silicic acid [8]. Free glycerol was estimated using isotope dilution mass spectrometry [9].

Table 1a. Certified Concentrations and Uncertainties for Analytes in SRM 1951a

| Analyte            | Level I<br>(in mmol/L) | Level II<br>(in mmol/L) |
|--------------------|------------------------|-------------------------|
| Total Cholesterol  | 4.7109 ± 0.0116        | 7.1554 ± 0.0142         |
| Total Glycerides   | 1.1357 ± 0.0035        | 1.9477 ± 0.0066         |
| Triglycerides only | 1.0053 ± 0.0077        | 1.7462 ± 0.0107         |

Table 1b. Certified Concentrations and Uncertainties for Analytes in SRM 1951a

| Analyte            | Level I<br>(in mg/dL) <sup>a</sup> | Level II<br>(in mg/dL) <sup>a</sup> |
|--------------------|------------------------------------|-------------------------------------|
| Total Cholesterol  | 182.15 ± 0.45                      | 276.67 ± 0.55                       |
| Total Glycerides   | 100.56 ± 0.31                      | 172.46 ± 0.58                       |
| Triglycerides only | 89.01 ± 0.68                       | 154.62 ± 0.95                       |

<sup>a</sup> Total glycerides and triglycerides results are expressed as mg triolein per deciliter.

Each certified value is the mean of measurements made using the definitive method [3,4]. The expanded uncertainty,  $U$ , for each certified value is calculated from the equation  $U = ku_c$ , where  $u_c$  is the combined standard uncertainty calculated according to the ISO Guide [10] and  $k$  is a coverage factor. The value  $u_c$  is intended to represent, at the level of one standard deviation, the uncertainty in mean concentration from the combined effect of measurement uncertainty and the uncertainty in the purity of the primary standards. The coverage factor,  $k = 2.306$ , is the Student's  $t$ -value for a 95 % confidence interval with eight degrees of freedom (df). Therefore, each certified value with its expanded uncertainty define a range of values within which the true concentration is expected to lie with approximately 95 % confidence.

Table 2. Combined Standard Uncertainties,  $u_c$ , and Degrees of Freedom, df, for the Data in Tables 1a and 1b

| Analyte            | mmol/L  |          | mg/dL   |          | Degrees of Freedom (df) |
|--------------------|---------|----------|---------|----------|-------------------------|
|                    | Level I | Level II | Level I | Level II |                         |
|                    | $u_c$   | $u_c$    | $u_c$   | $u_c$    |                         |
| Total Cholesterol  | 0.0049  | 0.0062   | 0.19    | 0.24     | 8                       |
| Total Glycerides   | 0.0015  | 0.0028   | 0.13    | 0.25     | 8                       |
| Triglycerides only | 0.0034  | 0.0046   | 0.30    | 0.41     | 8                       |

Table 3a. Reference Concentrations and Uncertainties<sup>a</sup> for Analytes in SRM 1951a in mmol/L  
based upon Results from the CDC Lipid Reference Laboratory

| Analyte                     | Level I<br>(in mmol/L) | Level II<br>(in mmol/L) |
|-----------------------------|------------------------|-------------------------|
| Total Cholesterol           | 4.766 ± 0.010          | 7.252 ± 0.016           |
| HDL-Cholesterol             | 1.2318 ± 0.0083        | 1.259 ± 0.012           |
| LDL-Cholesterol             | 2.916 ± 0.017          | 4.838 ± 0.034           |
| Triglycerides <sup>b</sup>  | 1.0962 ± 0.0095        | 1.893 ± 0.024           |
| Glycerol Blank <sup>b</sup> | 0.0431 ± 0.0046        | 0.0632 ± 0.0033         |

Table 3b. Reference Concentrations and Uncertainties<sup>a</sup> for Analytes in SRM 1951a in mg/dL  
based upon Results from the CDC Lipid Reference Laboratory

| Analyte                     | Level I<br>(in mg/dL) | Level II<br>(in mg/dL) |
|-----------------------------|-----------------------|------------------------|
| Total Cholesterol           | 184.30 ± 0.40         | 280.39 ± 0.60          |
| HDL-Cholesterol             | 47.63 ± 0.32          | 48.67 ± 0.46           |
| LDL-Cholesterol             | 112.73 ± 0.65         | 187.1 ± 1.3            |
| Triglycerides <sup>b</sup>  | 97.06 ± 0.84          | 167.6 ± 2.1            |
| Glycerol Blank <sup>b</sup> | 3.82 ± 0.41           | 5.60 ± 0.29            |

<sup>a</sup> The uncertainties in the reference values are 95 % confidence intervals on the mean concentrations calculated according to the ISO guide [10]. The expanded uncertainties are of the form  $U = ku_c$ , where  $u_c$  is a standard uncertainty including both between-run and within-run variability, and  $k$  is a percentile of a Student's- $t$  distribution having appropriate degrees of freedom.

<sup>b</sup> Triglycerides and glycerol results are expressed as mg triolein per deciliter.

Most U.S. NIH funded epidemiological and interventional studies performed over the last 30 years have traced their total cholesterol, HDL-cholesterol, LDL-cholesterol, and triglyceride values to the reference methods performed at the CDC Lipid Reference Laboratory. As shown in Tables 1a, 1b, 3a, and 3b, there is a small bias in the CDC reference method values for total cholesterol (about 1.2 % to 1.3 % high) compared to NIST's definitive method values. The slight bias appears to be due to a small amount of nonspecificity of the CDC's Abell Kendall based reference method which has been discussed in some detail previously [11,12]. The National Cholesterol Education Program (NCEP) recommends that total cholesterol measurements be traceable to the CDC reference method [13,14]. Thus, NIST and the College of American Pathologists (CAP) anticipate that most manufacturers of total cholesterol reagents and calibrator materials, at least for distribution in the U.S., will wish to use the CDC reference values (i.e., 184.30 mg/dL and 280.39 mg/dL for Levels I and II, respectively) and not the NIST definitive method values at this time.

For the measurement of triglycerides, manufacturers and laboratories that actually measure total glycerides (i.e., no correction for glycerol blank) should use the NIST certified values for total glycerides (i.e., 100.56 mg/dL and 172.46 mg/dL as triolein for Levels I and II, respectively). The CDC reference method for triglycerides appears to detect a small percentage of mono- and diglycerides that may be present in both reference materials and clinical specimens, but it does not detect free glycerol [4]. Therefore, those manufacturers and clinical laboratories that measure a glycerol blanked or "net" triglyceride should use the CDC reference values for triglycerides (i.e., 97.06 mg/dL and 167.6 mg/dL for Levels I and II, respectively).



## REFERENCES

- [1] "Development of Definitive Methods for the National Reference System for the Clinical Laboratory, Approved Guideline," NCCLS Publication NRSL 1-A, National Committee for Clinical Laboratory Standards, Wayne, PA, (1991).
- [2] U.S. Department of Health and Human Services, "Biosafety in Microbiological and Biomedical Laboratories," U.S. Government Printing Office, Washington DC, (1988).
- [3] Ellerbe, P., Meiselman, S., Sniegowski, L.T., Welch, M.J., and White V, E., "Determination of Serum Cholesterol by a Modification of the Isotope Dilution Mass Spectrometric Definitive Method," *Anal. Chem.* **61**, pp. 1718-1723, (1989).
- [4] Ellerbe, P., Sniegowski, L.T., and Welch, M.J., "Isotope Dilution Mass Spectrometry as a Candidate Definitive Method for Determining Total Glycerides and Triglycerides in Serum," *Clin. Chem.* **41**, pp. 397-404, (1995).
- [5] Abell, L.L., Levy, B.B., Brodie, R.B., and Kendall, F.E., "Simplified Method for the Estimation of Total Cholesterol in Serum and Demonstration of its Specificity," *J. Biol. Chem.* **195**, pp. 357-366, (1952).
- [6] Cooper, G.R., Smith, S.J., Duncan, I.W., et al. "The Interlaboratory Testing of the Transferability of a Candidate Reference Method for Total Cholesterol in Serum," *Clin. Chem.* **32**, pp. 921-929, (1982).
- [7] Hainline, A., Karon, J., and Lippel, K. (eds.) "Manual of Laboratory Operations: Lipid and Lipoprotein Analysis," HEW Pub. No. 1 (NIH) pp. 75-628 (rev.). U.S. Gov. Printing Office Pub. No., 678, pp. 361-132, (1982).
- [8] Stein, E.A. and Myers, G.L., "National Cholesterol Education Panel Program Recommendations for Triglyceride Measurement: Executive Summary," *Clin. Chem.* **41**, pp. 1421-1426, (1995).
- [9] Bernert, J.T., Bell, C.J., McGuffey, J.E., and Waymack, P.P., "Determination of Free Glycerol in Human Serum Reference Materials by Isotope Dilution Gas Chromatography/Mass Spectrometry," *J. Chromatogr.* **578**, pp. 1-7, (1992).
- [10] *Guide to the Expression of Uncertainty in Measurement*, ISBN 92-67-10188-9, 1st Ed., ISO, Geneva, Switzerland, (1993): see also Taylor, B.N. and Kuyatt, C.E., "Guidelines for Evaluating and Expressing the Uncertainty of NIST Measurement Results," NIST Technical Note 1297, U.S. Government Printing Office, Washington DC, (1994).
- [11] Bernert, J.T., Akins, J.R., Cooper, G.R., Poulouse, A.K., Myers, G.L., and Sampson, E.R., "Factors Influencing the Accuracy of the National Reference System Total Cholesterol Reference Method," *Clin. Chem.* **37**, pp. 2053-2063, (1991).
- [12] Ellerbe, P., Myers, G.L., Cooper, G.R., Hertz, H.S., Sniegowski, L.T., Welch, M.J., "A Comparison of Results for Cholesterol in Human Serum Obtained by the Reference Method and by the Definitive Method of the National Reference System for Cholesterol," *Clin. Chem.* **36**, pp. 370-375, (1990).
- [13] National Cholesterol Education Program Laboratory Standardization Panel, "Current Status of Blood Cholesterol Measurement in Clinical Laboratories in the United States," *Clin Chem.* **34**, pp. 193-201, (1988).
- [14] Recommendations for Improving Cholesterol Measurement, National Heart, Lung, and Blood Institute, National Institutes of Health Publication No. 90-2964, Bethesda, MD, (1990).
- [15] Ellerbe, P., Sniegowski, L.T., Welch, M.J., "Isotope Dilution Mass Spectrometry as a Candidate Definitive Method for Determining Total Glycerides and Triglycerides in Serum," *Clin. Chem.* **41**, pp. 397-404, (1995).

**Certificate Revision History:** 4 Mar 99 (The concentrations for HDL- and LDL-cholesterol have been revised based upon new data received from CDC.); 24 Jun 97 (original certificate).

*Users of this SRM should ensure that the certificate in their possession is current. This can be accomplished by contacting the SRM Program at: Telephone (301) 975-6776 (select "Certificates"), Fax (301) 926-4751, e-mail [srminfo@nist.gov](mailto:srminfo@nist.gov), or via the Internet: <http://ts.nist.gov/srm>.*